Physician profile
Isaac Turner
NPI 1053335067
$6,542.25
in general payments reported to CMS, 2019-2025
37 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $95.28 · 2021: $374 · 2022: $1,040 · 2023: $1,807 · 2024: $1,412 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,578 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,578.33 |
| Education | $107.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,195.49 | 2021-2025 | Nayzilam, Briviact, Cimzia |
| Novartis Pharmaceuticals Corporation | $708.80 | 2020-2025 | |
| Abbvie INC. | $575.90 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $422.38 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $380.43 | 2022-2023 | Trudhesa |
| Celgene Corporation | $340.91 | 2022-2025 | Zeposia |
| Acorda Therapeutics, INC | $252.63 | 2019-2024 | Inbrija |
| Neurelis, INC. | $248.33 | 2022-2025 | Valtoco |
| Amgen INC. | $242.62 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $225.35 | 2019-2024 | Austedo Xr, Austedo |
| Argenx US, INC. | $205.57 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Tanabe Pharma America, INC. | $204.90 | 2019-2025 | Radicava |
| Genentech USA, INC. | $199.15 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Lundbeck LLC | $181.62 | 2024-2025 | Vyepti |
| Sk Life Science, INC. | $162.66 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $157.23 | 2022-2023 | Adlarity |
| Neurocrine Biosciences, INC. | $92.59 | 2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $91.94 | 2019-2024 | Nuplazid |
| Axsome Therapeutics, INC. | $74.70 | 2025 | Symbravo |
| Upsher-Smith Laboratories LLC | $57.60 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.34 | 2022 | |
| Eisai INC. | $53.50 | 2025 | |
| Alexion Pharmaceuticals, INC. | $49.43 | 2019-2024 | Ultomiris |
| Kyowa Kirin, INC. | $47.85 | 2023-2024 | Nourianz |
| Lilly USA, LLC | $41.11 | 2024-2025 | Kisunla, Emgality |
| Genzyme Corporation | $38.55 | 2019-2022 | |
| Biogen, INC. | $36.18 | 2021 | |
| Vanda Pharmaceuticals INC. | $32.13 | 2025 | Ponvory |
| Zyla Life Sciences, INC. | $27.63 | 2019 | |
| Bausch Health US, LLC | $25.03 | 2019 | |
| Tg Therapeutics, INC. | $23.77 | 2023 | |
| Sunovion Pharmaceuticals INC. | $19.19 | 2022 | |
| Allergan, INC. | $16.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.99 | 2025 | Hyqvia |
| Promius Pharma LLC | $14.07 | 2019 | |
| Validus Pharmaceuticals LLC | $12.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.